Vascular endothelial growth factor receptors and the therapeutic targeting of angiogenesis in cancer: Where do we go from here?

Cell Communication and Adhesion

Volumn 18, Issue 5, 2011, Pages 85-103

  Bruce, David ^a   Tan, Peng H ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Cancer; Endothelial cell; Growth factor; Monoclonal antibody; Tyrosine kinase inhibitor (TKI); VEGF; VEGFR

Indexed keywords

3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; 5 [(5 FLUORO 1,2 DIHYDRO 2 OXO 3H INDOL 3 YLIDENE)METHYL] N (2 HYDROXY 3 MORPHOLINOPROPYL) 2,4 DIMETHYL 1H PYRROLE 3 CARBOXAMIDE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ALACIZUMAB PEGOL; ANGIOZYME; ANTINEOPLASTIC AGENT; AXITINIB; BAY 579352; BRIVANIB; BRIVANIB ALANINATE; CEDIRANIB; CELL RECEPTOR; DOVITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ICRUCUMAB; INTEDANIB; MONOCLONAL ANTIBODY IMC 1C11; MOTESANIB; NEUROPILIN; NEUROPILIN 1; NEUROPILIN 2; ORANTINIB; OSI 930; PAZOPANIB; PEGDINETANIB; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; RAMUCIRUMAB; RPI 4610; SORAFENIB; SUNITINIB; TELATINIB; TIVOZANIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VATALANIB; XL 647; XL 999; ZD 2171; ZK 304709;

ABDOMINAL PAIN; ALOPECIA; ANGIOGENESIS; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTHRALGIA; BLEEDING; BLOOD VESSEL PERMEABILITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DEFECATION DISORDER; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; DYSARTHRIA; DYSPNEA; ELECTROLYTE DISTURBANCE; ENDOTHELIUM CELL; FATIGUE; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPOTHYROIDISM; LEUKOCYTOSIS; LUNG HEMORRHAGE; LYMPHANGIOGENESIS; LYMPHOCYTOPENIA; MOLECULAR INTERACTION; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEINURIA; PRURITUS; RASH; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; THROMBOCYTOSIS; TREATMENT INDICATION; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; VOMITING; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 83255176122     PISSN: 15419061     EISSN: 15435180     Source Type: Journal    
DOI: 10.3109/15419061.2011.619673     Document Type: Review

References (158)

1. Akino T, Hida K, Hida Y, Tsuchiya K, Freedman D, Muraki C, Ohga N, Matsuda K, Akiyama K, Harabayashi, T, Shinohara N, Nonomura K, Klagsbrun M, and Shindoh M (2009). Cytogenetic Abnormalities of Tumor-Associated Endothelial Cells in Human Malignant Tumors. Am J Pathol . 175: 2657-2667.
2. André T, Kotelevets L, Vaillant J-C, Coudray AM, Weber L, Pré vot S, Parc R, Gespach C, and Chastre E (2000). Vegf, vegf-B, vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. Interl J Cancer . 86: 174-181. (Pubitemid 30180811)
3. Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D, Kroll J, Plaisance S, de Mol M, Bono F, Kliche S, Fellbrich G, Ballmer-Hofer K, Maglione D, Mayr- Beyrle U, Dewerchin M, Dombrowski S, Stanimirovic D, Van Hummelen P, Dehio C, Hicklin DJ, Persico G, Herbert J-M, Communi D, Shibuya M, Collen D, Conway EM, and Carmeliet P (2003). Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med . 9: 936-943. (Pubitemid 36889938)
4. Azam F, Mehta S, and Harris AL (2010). Mechanisms of resistance to antiangiogenesis therapy. Eur J Cancer . 46: 1323-1332.
5. Bae D-G, Kim T-D, Li G, Yoon W-H, and Chae C-B (2005). Anti-Flt1 Peptide, a Vascular Endothelial Growth Factor Receptor 1-Specifi c Hexapeptide, Inhibits Tumor Growth and Metastasis. Clin Cancer Res . 11: 2651-2661. (Pubitemid 40569466)
6. Bagri A, Berry L, Gunter B, Singh M, Kasman I, Damico LA, Xiang H, Schmidt M, Fuh G, Hollister B, Rosen O, and Plowman GD (2010). Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment Effi cacy. Clin Cancer Res . 16: 3887-3900.
7. Bando H, Weich HA, Brokelmann M, Horiguchi S, Funata N, Ogawa T, and Toi M (2005). Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. Br J Cancer . 92: 553-561. (Pubitemid 40395537)
8. Banerjee S, A'hern R, Detre S, Littlewood-Evans AJ, Evans DB, Dowsett M, and Martin L-A (2010). Biological Evidence for Dual Antiangiogenic-Antiaromatase Activity of the VEGFR Inhibitor PTK787/ZK222584 In vivo. Clin Cancer Res . 16 : 4178-4187.
9. Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y, Grogan TM, and List AF (2001). Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood . 97: 1427-1434. (Pubitemid 32183769)
10. Bergers G, Brekken R, Mcmahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, and Hanahan D (2000). Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol . 2: 737-744.
11. Birk DM, Barbato J, Mureebe L, and Chaer RA (2009). Basic Science Review: Current Insights on the Biology and Clinical Aspects of VEGF Regulation. Vasc Endovasc Surg . 42: 517-530.
12. Boehm T, Folkman J, Browder T, and O'reilly MS (1997). Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature . 390: 404-407. (Pubitemid 28027321)
13. Bogos K, Renyi-Vamos F, Dobos J, Kenessey I, Tovari J, Timar J, Strausz J, Ostoros G, Klepetko W, Ankersmit HJ, Lang G, Hoda MA, Nierlich P, and Dome B (2009). High VEGFR-3-positive Circulating Lymphatic/Vascular Endothelial Progenitor Cell Level Is Associated with Poor Prognosis in Human Small Cell Lung Cancer. Clin Cancer Res . 15: 1741-1746.
14. Bradley DP, Tessier JJ, Lacey T, Scott M, Jürgensmeier JM, Odedra R, Mills J, Kilburn L, and Wedge SR (2009). Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate. Magn Reson Imag 27: 377-384.
15. Casanovas O, Hicklin DJ, Bergers G, and Hanahan D (2005). Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer cell . 8: 299-309. (Pubitemid 41443415)
16. Cascone T, Herynk MH, Xu L, Du Z, Kadara H, Nilsson MB, Oborn CJ, Park Y-Y, Erez B, Jacoby JJ, Lee J-S, Lin HY, Ciardiello F, Herbst RS, Langley RR, and Heymach JV (2011). Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. J Clin Invest . 121: 1313-1328.
17. Chae S-S, Kamoun WS, Farrar CT, Kirkpatrick ND, Niemeyer E, de Graaf AMA, Sorensen AG, Munn LL, Jain RK, and Fukumura D (2010). Angiopoietin-2 Interferes with Anti- VEGFR2-Induced Vessel Normalization and Survival Benefi t in Mice Bearing Gliomas. Clin Cancer Res . 16: 3618-3627.
18. Chang YT, Chang MC, Wei SC, Tien YW, Hsu C, Liang PC, Tsao PN, Jan IS, Wong JM. Serum Vascular Endothelial Growth Factor/Soluble Vascular Endothelial Growth Factor Receptor 1 Ratio Is an Independent Prognostic Marker in Pancreatic Cancer. Pancreas . 37(2): 145-150.
19. Cheng H and Force T (2010). Molecular Mechanisms of Cardiovascular Toxicity of Targeted Cancer Therapeutics. Circ Res . 106: 21-34.
20. Clinicaltrials.Gov (2010). A Phase III Study to Assess the Effi cacy of ZD6474 (ZACTIMA ™ ) Plus Best Supportive Care Versus Best Supportive Care in Patients With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer After Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI). NCT00404924, http://www.clinicaltrials.gov/ct2/ show/NCT00404924?term=6474+egfr.andrank=1.
21. Clinicaltrials.Gov (2011a). A Phase 1b, Open-label, Multicenter Study of (BMS-936564) in Combination With Lenalidomide (Revlimid) Plus Low-dose Dexamethasone, or With Bortezomib (Velcade) Plus Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma. NCT01359657, http://www.clinicaltrials. gov/ct2/show/NCT01359657?term=SDF+inhibitor.andrank=6.
22. Clinicaltrials.Gov (2011b). A Phase I Study of MK0752, a Notch Inhibitor, in Patients With Metastatic or Locally Advanced Breast Cancer and Other Solid Tumors. NCT00106145, http://www.clinicaltrials.gov/ct2/show/NCT00106145?term= notch+inhibitor+cancer.andrank+2.
23. Clinicaltrials.Gov (2011c). A Phase III Randomized Study of Brivanib Alaninate (BMS-582664) in Combination With Cetuximab (Erbitux®) Versus Placebo in Combination With Cetuximab (Erbitux®) in Patients With K-RAS Tumors Previously Treated With Combination Chemotherapy for Metastatic Colorectal Carcinoma. NCT00640471, http://www.clinicaltrials.gov/ct2/show/ NCT00640471?term=bms+582664&phase=23&rank=1.
24. Clinicaltrials.Gov (2011d). A Randomized, Double-blind, Multicenter Phase III Study of Brivanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Asian Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed or Are Intolerant to Sorafenib. NCT01108705, http:// www.clinicaltrials.gov/ct2/ show/NCT01108705?term=bms+582664&phase=23&rank=2.
25. Cross MJ and Claesson-Welsh L (2001). FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci . 22: 201-207. (Pubitemid 32244307)
26. Cross MJ, Dixelius J, Matsumoto T, and Claesson-Welsh L (2003). VEGF-receptor signal transduction. Trend Biochem Sci . 28: 488-494. (Pubitemid 38340413)
27. Dawson MR, Duda DG, Fukumura D, and Jain RK (2009). VEGFR1-activity- independent metastasis formation. Nature . 461: E4-E4.
28. Dayanir V, Meyer RD, Lashkari K, and Rahimi N (2001). Identifi cation of Tyrosine Residues in Vascular Endothelial Growth Factor Receptor-2/FLK-1 Involved in Activation of Phosphatidylinositol 3-Kinase and Cell Proliferation. J Biol Chem . 276: 17686-17692.
29. Demetri GD, Van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, Mcarthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, and Casali PG (2006). Effi cacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet . 368: 1329-1338. (Pubitemid 44528723)
30. Deng M, Huang H, Jin H, Dirsch O, and Dahmen U (2010). The anti-proliferative side effects of AEE788, a tyrosine kinase inhibitor blocking both EGF- and VEGF-receptor, are liversize- dependent after partial hepatectomy in rats. Invest New Drugs. 1-14.
31. Dias S, Hattori K, Heissig B, Zhu Z, Wu Y, witte L, Hicklin DJ, Tateno M, Bohlen P, Moore MAS, and Rafi i S (2001). Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci USA . 98: 10857-10862. (Pubitemid 32878709)
32. Dixelius J, Mäkinen T, Wirzenius M, Karkkainen MJ, Wernstedt C, Alitalo K, and Claesson-Welsh L (2003). Ligand-induced Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3) Heterodimerization with VEGFR-2 in Primary Lymphatic Endothelial Cells Regulates Tyrosine Phosphorylation Sites. J Biol Chem . 278: 40973-40979. (Pubitemid 37280919)
33. Dougher M and Terman BI (1999). Autophosphorylation of KDR in the kinase domain is required for maximal VEGFstimulated kinase activity and receptor internalization. Oncogene . 18: 29.
34. Ebos JML, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, and Kerbel RS (2009). Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis. Cancer Cell . 15: 232-239.
35. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, and Bukowski RM (2007). Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma. New Engl J Med . 356: 125-134. (Pubitemid 46089673)
36. Eskens FALM and VERWEIJ J (2006). The clinical toxicity profi le of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review. Eur J Cancer . 42: 3127-3139. (Pubitemid 44869016)
37. Fan F, Wey JS, Mccarty MF, Belcheva A, Liu W, Bauer TW, Somcio RJ, Wu Y, Hooper A, Hicklin DJ, and Ellis LM (2005). Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. 24: 2647-2653.
38. Fischer C, Mazzone M, Jonckx B, and Carmeliet P (2008). FLT1 and its ligands VEGFB and PlGF: drug targets for antiangiogenic therapy? Nat Rev Cancer . 8: 942-956.
39. Folkman J (1990). What Is the Evidence That Tumors Are Angiogenesis Dependent? J Natl Cancer Inst. 82: 4-7.
40. Frank NY, Schatton T, Kim S, Zhan Q, Wilson BJ, Ma J, Saab KR, Osherov V, Widlund HR, Gasser M, Waaga-Gasser A-M, Kupper TS, Murphy GF, and Frank MH (2011). VEGFR-1 Expressed by Malignant Melanoma-Initiating Cells Is Required for Tumor Growth. Cancer Res . 71: 1474-1485.
41. George S, Lal R, Camidge DR, Arkenau H, Chick J, Poondru S, Yap TA, Eckhardt SG, Demetri GD, and Scurr M (2009). Final results of a dose escalation (DE), pharmacokinetic (PK), and pharmacodynamic (PD) study of two schedules of OSI-930 in patients (pts) with advanced solid tumors. J Clin Oncol (Meeting Abstracts) . 27: 3564.
42. GHANEM, M. A., VAN STEENBRUGGE, G. J., SUDARYO, M. K., MATHOERA, R. B., NIJMAN, J. M. , and VAN DER KWAST, T. H. 2003. Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma. J Clin Pathol, 56, 107-113. (Pubitemid 36177252)
43. Gille H, Kowalski J, Yu L, Chen H, Pisabarro MT, Davis-Smyth T, and Ferrara N (2000). A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3[prime]-kinase activation and endothelial cell migration. EMBO J . 19: 4064-4073. (Pubitemid 30608545)
44. Gille J, Heidenreich R, Pinter A, Schmitz J, Boehme B, Hicklin DJ, Henschler R, and Breier G (2007). Simultaneous blockade of VEGFR-1 and VEGFR-2 activation is necessary to effi ciently inhibit experimental melanoma growth and metastasis formation. Internatl J Cancer . 120: 1899-1908. (Pubitemid 46418365)
45. Goldman CK, Kendall RL, Cabrera G, Soroceanu L, Heike Y, Gillespie GY, Siegal GP, Mao X, Bett AJ, Huckle WR, Thomas KA, and Curiel DT (1998). Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA . 95: 8795-8800. (Pubitemid 28350568)
46. Gombos Z, Xu X, Chu CS, Zhang PJ, and Acs G (2005). Peritumoral Lymphatic Vessel Density and Vascular Endothelial Growth Factor C Expression in Early-Stage Squamous Cell Carcinoma of the Uterine Cervix. Clin Cancer Res . 11: 8364-8371. (Pubitemid 41746949)
47. Gomez-Rivera F, Santillan-Gomez AA, Younes MN, Kim S, Fooshee D, Zhao M, Jasser SA, and Myers JN (2007). The Tyrosine Kinase Inhibitor, AZD2171, Inhibits Vascular Endothelial Growth Factor Receptor Signaling and Growth of Anaplastic Thyroid Cancer in an Orthotopic Nude Mouse Model. Clin Cancer Res . 13: 4519-4527. (Pubitemid 47219722)
48. Graepler F, Verbeek B, Graeter T, Smirnow I, Kong HL, Schuppan D, Bauer M, Vonthein R, Gregor M, and Lauer UM (2005). Combined endostatin/sFlt-1 antiangiogenic gene therapy is highly effective in a rat model of HCC. Hepatology. 41: 879-886. (Pubitemid 40462951)
49. Hamada K, Oike Y, Takakura N, Ito Y, Jussila L, Dumont DJ, Alitalo K, and Suda T (2000). VEGF-C signaling pathways through VEGFR-2 and VEGFR-3 in vasculoangiogenesis and hematopoiesis. Blood . 96: 3793-3800.
50. He Y, Kozaki K-I, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, and Alitalo, K (2002). Suppression of Tumor Lymphangiogenesis and Lymph Node Metastasis by Blocking Vascular Endothelial Growth Factor Receptor 3 Signaling. J Natl Cancer Inst . 94: 819-825. (Pubitemid 34705053)
51. Hicklin DJ and Ellis LM (2005). Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis. J Clin Oncol . 23: 1011-1027. (Pubitemid 46202320)
52. Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, Kijima H, Shipley JM, Senior RM, and Shibuya M (2002). MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specifi c metastasis. Cancer Cell. 2: 289-300. (Pubitemid 41043963)
53. Holmqvist K, Cross MJ, Rolny C, Hägerkvist R, Rahimi N, Matsumoto T, Claesson- Welsh L, and Welsh M (2004). The Adaptor Protein Shb Binds to Tyrosine 1175 in Vascular Endothelial Growth Factor (VEGF) Receptor-2 and Regulates VEGF-dependent Cellular Migration. J Biol Chem . 279: 22267-22275. (Pubitemid 38679423)
54. Hoshida T, Isaka N, Hagendoorn J, Di Tomaso E, Chen Y-L, Pytowski B, Fukumura D, Padera TP, and Jain RK (2006). Imaging Steps of Lymphatic Metastasis Reveals That Vascular Endothelial Growth Factor-C Increases Metastasis by Increasing Delivery of Cancer Cells to Lymph Nodes: Therapeutic Implications. Cancer Res . 66: 8065-8075. (Pubitemid 44299172)
55. Houck KA, Leung DW, Rowland AM, Winer J, and Ferrara N (1992). Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem . 267: 26031-26037. (Pubitemid 23014012)
56. Hu Q, Dey AL, Yang Y, Shen Y, Jilani IB, Estey EH, Kantarjian HM, Giles FJ, and Albitar M (2004). Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes. Cancer . 100: 1884-1891. (Pubitemid 38529566)
57. Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian C-N, Kahnoski R, Futreal PA, Furge KA, and Teh BT (2010). Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma. Cancer Res . 70: 1063-1071.
58. Huang K, Andersson C, Roomans GM, Ito N, and Claesson-Welsh L (2001). Signaling properties of VEGF receptor-1 and -2 homoand heterodimers. Internl J Biochem Cell Biol . 33: 315-324. (Pubitemid 32324000)
59. Ilhan N, Ilhan N, and Deveci F (2004). Functional signifi cance of vascular endothelial growth factor and its receptor (receptor-1) in various lung cancer types. Clin Biochem . 37: 840-845. (Pubitemid 39141129)
60. Ivy SP, Wick JY, and Kaufman BM (2009). An overview of smallmolecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol . 6: 569-579.
61. Jackson MW, Roberts JS, Heckford SE, Ricciardelli C, Stahl J, Horsfall DJ, and Tilley WD (2002). A Potential Autocrine Role for Vascular Endothelial Growth Factor in Prostate Cancer. Cancer Res . 62: 854-859. (Pubitemid 34126964)
62. Jain R, Duda D, Clark J, and Loeffl er J (2006). Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nature Clin Prac . 3: 24-40. (Pubitemid 43108832)
63. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, Devore RF, Gaudreault J, Damico LA, Holmgren E, and Kabbinavar F (2004). Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. J Clin Oncol . 22: 2184-2191. (Pubitemid 41095154)
64. Kaipainen A, Korhonen J, Mustonen T, Van Hinsbergh VW, Fang GH, Dumont D, Breitman M, and Alitalo, K (1995). Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A . 92: 3566-3570.
65. Kaipainen A, Korhonen J, Pajusola K, Aprelikova O, Persico MG, Terman BI, and Alitalo K (1993). The related FLT4, FLT1, and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells. J Exp Med . 178: 2077-2088. (Pubitemid 23344864)
66. Kaplan RN, Rafi i S, and Lyden D (2006). Preparing the "Soil": The Premetastatic Niche. Cancer Res . 66: 11089-11093.
67. Kappas NC, Zeng G, Chappell JC, Kearney JB, Hazarika S, Kallianos KG, Patterson C, Annex BH, and Bautch VL (2008). The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood vessel branching. J Cell Biol . 181: 847-858. (Pubitemid 351786988)
68. Kashani-Sabet M (2004). Non-viral delivery of ribozymes for cancer gene therapy. Expert OpinBiolo Ther . 4: 1749-1755. (Pubitemid 39518108)
69. Kawamura H, Li X, Harper SJ, Bates DO, and Claesson-Welsh L (2008). Vascular Endothelial Growth Factor (VEGF)-A165b Is a Weak In vitro Agonist for VEGF Receptor-2 Due to Lack of Coreceptor Binding and Defi cient Regulation of Kinase Activity. Cancer Res . 68: 4683-4692.
70. Kearney JB, Kappas NC, Ellerstrom C, Dipaola FW, and Bautch VL (2004). The VEGF receptor fl t-1 (VEGFR-1) is a positive modulator of vascular sprout formation and branching morphogenesis. Blood . 103: 4527-4535. (Pubitemid 38745980)
71. Keyt BA, Berleau LT, Nguyen HV, Chen H, Heinsohn H, Vandlen R, and Ferrara N (1996). The Carboxyl-terminal Domain(111165) of Vascular Endothelial Growth Factor Is Critical for Its Mitogenic Potency. J Biol Chem . 271: 7788-7795. (Pubitemid 26111064)
72. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, and Ferrara N (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature . 362: 841-844. (Pubitemid 23132159)
73. Ko JS, Rayman, P, Ireland J, Swaidani S, Li G, Bunting KD, Rini B, Finke JH, and Cohen PA (2010). Direct and Differential Suppression of Myeloid-Derived Suppressor Cell Subsets by Sunitinib Is Compartmentally Constrained. Cancer Res . 70: 3526-3536.
74. Kozin SV, Boucher Y, Hicklin DJ, Bohlen P, Jain R, and Suit HD (2001). Vascular Endothelial Growth Factor Receptor-2-blocking Antibody Potentiates Radiation-induced Long-Term Control of Human Tumor Xenografts. Cancer Res . 61: 39-44. (Pubitemid 32095696)
75. Krishnamurthi SS, Lorusso PM, Goncalves PH, Fox F, Rowinsky EK, Schwartz J, and Youssoufi an H (2008). Phase 1 study of weekly anti-vascular endothelial growth factor receptor-1 (VEGFR-1) monoclonal antibody IMC-18F1 in patients with advanced solid malignancies. J Clin Oncol (Meeting Abs) . 26: 14630.
76. Kuenen BC, Rosen L, Smit EF, Parson MRN, Levi M, Ruijter R, Huisman H, Kedde MA, Noordhuis P, Van Der Vijgh WJF, Peters GJ, Cropp GF, Scigalla P, Hoekman K, Pinedo HM, and Giaccone G (2002). Dose-Finding and Pharmacokinetic Study of Cisplatin, Gemcitabine, and SU5416 in Patients With Solid Tumors. J Clin Oncol . 20: 1657-1667. (Pubitemid 34260548)
77. Kuwai T, Nakamura T, Sasaki T, Kitadai Y, Kim J-S, Langley R, Fan D, Wang X, Do K-A, Kim S-J, and Fidler I (2008). Targeting the EGFR, VEGFR, and PDGFR on colon cancer cells and stromal cells is required for therapy. Clin Exp Metastas . 25: 477-489.
78. Lamalice L, Houle F, Jourdan G, and Huot J (2004). Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2//p38. Oncogene . 23: 434-445. (Pubitemid 38174998)
79. Le Boeuf F, Houle F, and Huot J (2004). Regulation of Vascular Endothelial Growth Factor Receptor 2- mediated Phosphorylation of Focal Adhesion Kinase by Heat Shock Protein 90 and Src Kinase Activities. J Biol Chem . 279: 39175-39185. (Pubitemid 39296081)
80. Lee S, Jilani SM, Nikolova GV, Carpizo D, and Iruela-Arispe ML (2005). Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol . 169: 681-691. (Pubitemid 41002860)
81. Li H and Harris AL (2009). Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications. Front Biosci . 14: 16.
82. Li J-L, Sainson RC, Oon CE, Turley H, Leek R, Sheldon H, Bridges E, Shi W, Snell C, Bowden ET, Wu H, Chowdhury PS, Russell AJ, Montgomery CP, Poulsom R, and Harris AL (2011). DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res. 71: 6073-83.
83. Liu B, Earl HM, Baban D, Shoaibi M, Fabra A, Kerr DJ, and Seymour LW (1995). Melanoma Cell Lines Express VEGF Receptor KDR and Respond to Exogenously Added VEGF. Biochemical and Biophy Res Comm . 217: 721-727. (Pubitemid 26019716)
84. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, de Oliveira AC, Santoro A, Raoul J-L, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz J-F, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, and Bruix J (2008). Sorafenib in Advanced Hepatocellular Carcinoma. New Engl J Med . 359: 378-390.
85. Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, Nagy JA, Hooper A, Priller J, De Klerck B, Compernolle V, Daci E, Bohlen P, Dewerchin M, Herbert JM, Fava R, Matthys P, Carmeliet G, Collen D, Dvorak HF, Hicklin DJ, and Carmeliet P (2002). Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nature Med 8: 10.
86. Lyden H, Dias C, Blaikie B, Chadburn H, Marks W, Wu H, Zhu H, Crystal M, Hajjar M, BENEZRA , and RAFII (2001). Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nature Med . 7: 8.
87. Mahasreshti PJ, Navarro JG, Kataram M, Wang MH, Carey D, Siegal GP, Barnes MN, Nettelbeck DM, Alvarez RD, Hemminki A, and Curiel DT (2001). Adenovirus- mediated Soluble FLT-1 Gene Therapy for Ovarian Carcinoma. Clin Cancer Res . 7: 2057-2066. (Pubitemid 32994845)
88. Makinen T, Veikkola T, Mustjoki S, Karpanen T, Catimel B, Nice EC, Wise L, Mercer A, Kowalski H, Kerjaschki D, Stacker SA, Achen MG, and Alitalo K (2001). Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J . 20: 4762-4773. (Pubitemid 32848629)
89. Mamluk R, Carvajal IM, Morse BA, Wong H, Abramowitz J, Aslanian S, Lim AC, Gokemeijer J, Storek MJ, Lee J, Gosselin M, Wright MC, Camphausen RT, Wang J, Chen Y, Miller K, Sanders K, Short S, Sperinde J, Prasad G, Williams S, Kerbel R, Ebos J, Mutsaers A, Mendlein JD, Harris AS, and Furfi ne ES. (2010). Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2. MAbs . 2:199-208.
90. Marchiò S, Primo L, Pagano M, Palestro G, Albini A, Veikkola T, Cascone I, Alitalo K, and Bussolino F (1999). Vascular Endothelial Growth Factor-C Stimulates the Migration and Proliferation of Kaposi's Sarcoma Cells. J Biol Chem . 274: 27617-27622.
91. Marx GM, Steer CB, Harper P, Pavlakis N, Rixe O, and Khayat D (2002). Unexpected Serious Toxicity With Chemotherapy and Antiangiogenic Combinations: Time to Take Stock! J Clin Oncol . 20: 1446-1448. (Pubitemid 34260521)
92. Matsumoto T, Bohman S, Dixelius J, Berge T, Dimberg A, Magnusson P, Wang L, Wikner C, Qi JH, Wernstedt C, Wu J, Bruheim S, Mugishima H, Mukhopadhyay D, Spurkland A , and Claesson-Welsh L (2005). VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis. EMBO J . 24: 2342-2353. (Pubitemid 41032586)
93. Matsumura K, Hirashima M, Ogawa M, Kubo H, Hisatsune H, Kondo N, Nishikawa S, Chiba T, and Nishikawa S-I (2003). Modulation of VEGFR-2-mediated endothelial-cell activity by VEGF-C/VEGFR-3. Blood . 101: 1367-1374. (Pubitemid 36182508)
94. Mcmullen ME, Bryant PW, Glembotski CC, Vincent PA, and PUMIGLIA, K. M. 2005. Activation of p38 Has Opposing Effects on the Proliferation and Migration of Endothelial Cells. J Biol Chem . 280: 20995-21003. (Pubitemid 40805657)
95. Meadows KN, Bryant P, and Pumiglia K (2001). Vascular Endothelial Growth Factor Induction of the Angiogenic Phenotype Requires Ras Activation. J Biol Chem . 276: 49289-49298.
96. Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, Han LY, Landen CN, Jennings N, de Geest K, Langley RR, Villares G, Sanguino A, Lutgendorf SK, Lopez-Berestein G, Bar-ElI MM, and Sood AK (2008). Effect of Interleukin-8 Gene Silencing With Liposome-Encapsulated Small Interfering RNA on Ovarian Cancer Cell Growth. J Natl Cancer Inst . 100: 359-372. (Pubitemid 351480526)
97. Miles D, Harbeck N, Escudier B, Hurwitz H, Saltz L, Van Cutsem E, Cassidy J, Mueller B, and Sirzé n F (2011). Disease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials. J Clin Oncol . 29: 83-88.
98. Mimori K, Fukagawa T, Kosaka Y, Kita Y, Ishikawa K, Etoh T, Iinuma H, Sasako M, and Mori M (2008). Hematogenous Metastasis in Gastric Cancer Requires Isolated Tumor Cells and Expression of Vascular Endothelial Growth Factor Receptor-1. Clin Cancer Res . 14: 2609-2616.
99. Mizukami Y, Jo W-S, Duerr E-M, Gala M, Li J, Zhang X, Zimmer MA, Iliopoulos O, Zukerberg LR, Kohgo Y, Lynch MP, Rueda BR, and Chung DC (2005). Induction of interleukin-8 preserves the angiogenic response in HIF-1[alpha]-defi cient colon cancer cells. Nat Med . 11: 992-997. (Pubitemid 41294446)
100. Motzer R, Hutson T, Tomczak P, Michaelson M, Bukowski R, Rixe O, Oudard S, Negrier S, Szczylik C, Kim S, Chen I, Bycott P, Baum C, and Figlin R (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New Engl J Med . 356: 115-124. (Pubitemid 46089672)
101. Muller YA, Christinger HW, Keyt BA, and de Vos AM (1997). The crystal structure of vascular endothelial growth factor (VEGF) refi ned to 1.93 Å resolution: multiple copy fl exibility and receptor binding. Structure . 5: 1325-1338. (Pubitemid 27484475)
102. Natale RB, Bodkin D, Govindan R, Sleckman BG, Rizvi NA, Capó A, Germonpré P, Eberhardt WEE, Stockman PK, Kennedy SJ, and Ranson M (2009). Vandetanib Versus Gefi tinib in Patients With Advanced Non-Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study. J Clin Oncol . 27: 2523-2529.
103. Ng Y-S, Krilleke D, and Shima DT (2006). VEGF function in vascular pathogenesis. Exp Cell Res . 312: 527-537. (Pubitemid 43290330)
104. Olsson A-K, Dimberg A, Kreuger J, and Claesson-Welsh L (2006). VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol . 7: 359-371.
105. Padera TP, Kuo AH, Hoshida T, Liao S, Lobo J, Kozak KR, Fukumura D, and Jain R.K. (2008). Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib. Mol Cancer Ther . 7: 2272-2279.
106. Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, and Casanovas O (2009). Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis. Cancer cell . 15: 220-231.
107. Pajusola K, Aprelikova O, Korhonen J, Kaipainen A, Pertovaara L, Alitalo R, and Alitalo K (1992). FLT4 Receptor Tyrosine Kinase Contains Seven Immunoglobulin-like Loops and Is Expressed in Multiple Human Tissues and Cell Lines. Cancer Res . 52: 5738-5743.
108. Park J, Keller G, and Ferrara N (1993). The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extra cellular matrix-bound VEGF. Mol Biol Cell . 4: 1317-1326. (Pubitemid 24045761)
109. Park JE, Chen HH, Winer J, Houck KA, and Ferrara N (1994). Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affi nity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem . 269: 25646-25654.
110. Patel NS, Muneer A, Blick C, Arya M, and Harris AL (2009). Targeting Vascular Endothelial Growth Factor in Renal Cell Carcinoma. Tumor Biol . 30: 292-299.
111. Patel RR, Sengupta S, Kim HR, Klein-Szanto AJ, Pyle JR, Zhu F, Li T, Ross EA, Oseni S, Fargnoli J, and Jordan V C (2010). Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: A potential clinical application of angiogenesis inhibitors. Eur J Cancer (Oxford, England : 1990) . 46: 1537-1553.
112. Plate KH, Breier G, Weich HA, Mennel HD, and Risau W (1994). Vascular endothelial growth factor and glioma angiogenesis: Coordinate induction of VEGF receptors, distribution of VEGF protein and possible In vivo regulatory mechanisms. Intl J Cancer . 59: 520-529. (Pubitemid 24357278)
113. Polverino A, Coxon A, Starnes C, Diaz Z, Demelfi T, Wang L, Bready J, Estrada J, Cattley R, Kaufman S, Chen D, Gan Y, Kumar G, Meyer J, Neervannan S, Alva G, Talvenheimo J, Montestruque S, Tasker A, Patel V, Radinsky R, and Kendall R (2006). AMG 706, an Oral, Multikinase Inhibitor that Selectively Targets Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors, Potently Inhibits Angiogenesis and Induces Regression in Tumor Xenografts. Cancer Res . 66: 8715-8721. (Pubitemid 44449188)
114. Potapova O, Laird AD, Nannini MA, Barone A, Li G, Moss KG, Cherrington JM, and Mendel DB (2006). Contribution of individual targets to the antitumor effi cacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther . 5: 1280-1289. (Pubitemid 43881321)
115. Prewett M, Huber J, Li Y, Santiago A, O'connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L, Bohlen P, and Hicklin DJ (1999). Antivascular Endothelial Growth Factor Receptor (Fetal Liver Kinase 1) Monoclonal Antibody Inhibits Tumor Angiogenesis and Growth of Several Mouse and Human Tumors. Cancer Res . 59: 5209-5218. (Pubitemid 29503984)
116. Price DJ, Miralem T, Jiang S, Steinberg R, and Avraham H (2001). Role of Vascular Endothelial Growth Factor in the Stimulation of Cellular Invasion and Signaling of Breast Cancer Cells. Cell Growth Differ . 12: 129-135. (Pubitemid 32677998)
117. Rahimi N, Golde TE, and Meyer RD (2009). Identifi cation of Ligand-Induced Proteolytic Cleavage and Ectodomain Shedding of VEGFR-1/FLT1 in Leukemic Cancer Cells. Cancer Res . 69: 2607-2614.
118. Rebhun RB, Langley RR, Yokoi K, Fan D, Gershenwald JE, and Fidler IJ
119. Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, Maira G, Parati EA, Stassi G, Larocca LM, and de Maria R (2010). Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature . 468: 824-828.
120. Roberts N, Kloos B, Cassella M, Podgrabinska S, Persaud K, Wu Y, Pytowski B, and Skobe M (2006). Inhibition of VEGFR-3 Activation with the Antagonistic Antibody More Potently Suppresses Lymph Node and Distant Metastases than Inactivation of VEGFR-2. Cancer Res . 66: 2650-2657.
121. Robinson C and Stringer S (2001). The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci . 114: 853-865. (Pubitemid 32273121)
122. Rosen LS (2005). VEGF-Targeted Therapy: Therapeutic Potential and Recent Advances. Oncologist . 10: 382-391. (Pubitemid 40993566)
123. Ruhrberg C, Gerhardt H, Golding M, Watson R, Ioannidou S, Fujisawa H, Betsholtz C, and Shima DT (2002). Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev . 16: 2684-2698.
124. Saharinen P, Tammela T, Karkkainen MJ, and Alitalo K (2004). Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and infl ammation. Trends Immun . 25: 387-395. (Pubitemid 38780956)
125. Sallinen H, Anttila M, Grohn O, Koponen J, Hamalainen K, Kholova I, Kosma VM, Heinonen S, Alitalo K, and Yla- Herttuala S (2011). Cotargeting of VEGFR-1 and -3 and angiopoietin receptor Tie2 reduces the growth of solid human ovarian cancer in mice. Cancer Gene Ther . 18: 100-109.
126. Sandler A, Gray R, Perry M, Brahmer J, Schiller J, Dowlati A, Lilenbaum R, and Johnson D (2006). Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New Engl J Med . 355: 2542-2550. (Pubitemid 44917502)
127. Sarkar S, Mazumdar A, Dash R, Sarkar D, Fisher P, and Mandal M (2010). ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells. Cancer Biol Ther . 9: 592-693.
128. Schoppmann SF, Fenzl A, Nagy K, Unger S, Bayer G, Geleff S, Gnant M, Horvat R, Jakesz R, and Birner P (2006). VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival. Surgery . 139: 839-846. (Pubitemid 43902914)
129. Schwartz JD, Rowinsky EK, Youssoufi an H, Pytowski B, and Wu Y (2010). Vascular endothelial growth factor receptor-1 in human cancer. Cancer . 116: 1027-1032.
130. Senger DR, Connolly DT, Van de Water L, Feder J, and Dvorak HF (1990). Purifi cation and NH2-Terminal Amino Acid Sequence of Guinea Pig Tumor-secreted Vascular Permeability Factor. Cancer Res . 50: 1774-1778. (Pubitemid 20098819)
131. Seto T, Higashiyama M, Funai H, Imamura F, Uematsu K, Seki N, Eguchi K, Yamanaka T, and Ichinose Y (2006). Prognostic value of expression of vascular endothelial growth factor and its fl t-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer . 53: 91-96. (Pubitemid 43831360)
132. Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, Fuh G, Gerber H-P, and Ferrara N (2007). Tumor refractoriness to anti-VEGF treatment is mediated by CD11b + Gr1 + myeloid cells. Nat Biotech . 25: 911-920. (Pubitemid 47236916)
133. Smith NR, Baker D, James NH, Ratcliffe K, Jenkins M, Ashton SE, Sproat G, Swann R, Gray N, Ryan A, Jürgensmeier JM, and Womack C (2010). Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers. Clin Cancer Res . 16: 3548-3561.
134. Su J-L, Yang P-C, Shih J-Y, Yang C-Y, Wei L-H, Hsieh C-Y, Chou C-H, Jeng Y-M, Wang M-Y, Chang K-J, Hung M-C, and Kuo M-L (2006a). The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell . 9: 209-223. (Pubitemid 43357947)
135. Su JL, Yen CJ, Chen PS, Chuang SE, Hong CC, Kuo IH, Chen HY, Hung MC, and Kuo ML (2006b). The role of the VEGF-C/ VEGFR-3 axis in cancer progression. Br J Cancer . 96: 541-545.
136. Takahashi T, Yamaguchi S, Chida K, and Shibuya M (2001). A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-[gamma] and DNA synthesis in vascular endothelial cells. EMBO J . 20: 2768-2778. (Pubitemid 32938560)
137. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, and Abraham JA (1991). The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem . 266: 11947-11954.
138. Tozer GM, Akerman S, Cross NA, Barber PR, Björndahl MA, Greco O, Harris S, Hill S A, Honess DJ, Ireson CR, Pettyjohn KL, Prise VE, Reyes-Aldasoro CC, Ruhrberg C, Shima DT, and Kanthou C (2008). Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform-Producing Tumors. Cancer Res . 68: 2301-2311. (Pubitemid 351521804)
139. USNIH (2010). ClinicalTrials.gov [Online]. Available: http://www.clinicaltrials.gov/ct2/home (accessed 20/05/11).
140. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, and Alitalo, K 1996. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 15: 9.
141. Varey AHR, Rennel ES, Qiu Y, Bevan HS, Perrin RM, Raffy S, Dixon AR, Paraskeva C, Zaccheo O, Hassan AB, Harper SJ, and Bates DO (2008). VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. Br J Cancer . 98: 1366-1379. (Pubitemid 351543576)
142. Vincent L, Jin DK, Karajannis MA, Shido K, Hooper AT, Rashbaum WK, Pytowski B, Wu Y, Hicklin DJ, Zhu Z, Bohlen P, Niesvizky R, and Rafi i S (2005). Fetal Stromal-Dependent Paracrine and Intracrine Vascular Endothelial Growth Factor-A/Vascular Endothelial Growth Factor Receptor-1 Signaling Promotes Proliferation and Motility of Human Primary Myeloma Cells. Cancer Res . 65: 3185-3192. (Pubitemid 40524600)
143. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, and Heldin CH (1994). Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem . 269: 26988-26995. (Pubitemid 24332901)
144. Wan PTC, Garnett MJ, Roe SM, lee S, Niculescu-Duvaz D, Good VM, Project CG, Jones CM, Marshall CJ, Springer CJ, Barford D, and Marais R (2004). Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF. Cell . 116: 855-867. (Pubitemid 38410730)
145. Wang F-Q, Barfi eld E, Dutta S, Pua T, and Fishman DA (2009). VEGFR-2 silencing by small interference RNA (siRNA) suppresses LPA-induced epithelial ovarian cancer (EOC) invasion. Gynecologic Oncology . 115: 414-423.
146. Welti JC, Gourlaouen M, Powles T, Kudahetti SC, Wilson P, Berney DM, and Reynolds AR (2011). Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene . 30: 1183-1193.
147. Wilmes LJ, Pallavicini MG, Fleming LM, Gibbs J, Wang D, Li K-L, Partridge SC, Henry RG, Shalinsky DR, Hu-Lowe D, Park JW, Mcshane TM, Lu Y, Brasch RC, and Hylton NM (2007). AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imag . 25: 319-327. (Pubitemid 46413652)
148. Winkler F, Kozin SV, Tong RT, Chae S-S, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, Di Tomaso E, Munn LL, and Jain RK (2004). Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell . 6: 553-563. (Pubitemid 40017699)
149. Woolard J, Wang W-Y, Bevan HS, Qiu Y, Morbidelli L, Pritchard- Jones RO, Cui T-G, Sugiono M, Waine E, Perrin R, Foster R, Digby-Bell J, Shields JD, Whittles CE, Mushens RE, Gillatt DA, Ziche M, Harper S J, and Bates DO (2004). VEGF165b, an Inhibitory Vascular Endothelial Growth Factor Splice Variant. Cancer Res . 64: 7822-7835.
150. Wu Y, Zhong Z, Huber J, Bassi R, Finnerty B, Corcoran E, Li H, Navarro E, Balderes P, Jimenez X, Koo H, Mangalampalli VRM, Ludwig DL, Tonra JR, and Hicklin DJ (2006). Anti- Vascular Endothelial Growth Factor Receptor-1 Antagonist Antibody as a Therapeutic Agent for Cancer. Clin Cancer Res . 12: 6573-6584. (Pubitemid 44799733)
151. Xiong Y-Q, Sun H-C, Zhang W, Zhu X-D, Zhuang P-Y, Zhang J-B, Wang L, Wu W-Z, Qin L-X, and Tang Z-Y (2009). Human Hepatocellular Carcinoma Tumor-derived Endothelial Cells Manifest Increased Angiogenesis Capability and Drug Resistance Compared with Normal Endothelial Cells. Clin Cancer Res . 15: 4838-4846.
152. Xu L, Duda DG, Di Tomaso E, Ancukiewicz M, Chung DC, Lauwers GY, Samuel R, Shellito P, Czito BG, Lin P-C, Poleski M, Bentley R, Clark JW, Willett CG, and Jain RK (2009). Direct Evidence that Bevacizumab, an Anti-VEGF Antibody, Upregulates SDF1, CXCR4, CXCL6, and Neuropilin 1 in Tumors from Patients with Rectal Cancer. Cancer Res . 69: 7905-7910.
153. Yamaoka-Tojo M, Ushio-Fukai M, Hilenski L, Dikalov SI, Chen YE, Tojo T, Fukai T, Fujimoto M, Patrushev NA, Wang N, Kontos CD, Bloom GS, and Alexander RW (2004). IQGAP1, a Novel Vascular Endothelial Growth Factor Receptor Binding Protein, Is Involved in Reactive Oxygen Species-Dependent Endothelial Migration and Proliferation. Circ Res . 95: 276-283. (Pubitemid 39056288)
154. Yang AD, Camp ER, Fan F, Shen L, Gray MJ, Liu W, Somcio R, Bauer TW, Wu Y, Hicklin DJ, and Ellis LM (2006). Vascular Endothelial Growth Factor Receptor-1 Activation Mediates Epithelial to Mesenchymal Transition in Human Pancreatic Carcinoma Cells. Cancer Res . 66: 46-51. (Pubitemid 43166007)
155. Yashiro M, Shinto O, Nakamura K, Tendo M, Matsuoka T, Matsuzaki T, Kaizaki R, Ohira M, Miwa A, and Hirakawa K (2009). Effects of VEGFR-3 phosphorylation inhibitor on lymph node metastasis in an orthotopic diffuse-type gastric carcinoma model. Br J Cancer . 101:1100-1106.
156. Yokoi K, Thaker PH, Yazici S, Rebhun RR, Nam D-H, He J, Kim S-J, Abbruzzese JL, Hamilton SR, and Fidler, IJ (2005). Dual Inhibition of Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor Phosphorylation by AEE788 Reduces Growth and Metastasis of Human Colon Carcinoma in an Orthotopic Nude Mouse Model. Cancer Res . 65: 3716-3725. (Pubitemid 40616349)
157. Youssoufi an H, Hicklin DJ, and Rowinsky EK (2007). Review: Monoclonal Antibodies to the Vascular Endothelial Growth Factor Receptor-2 in Cancer Therapy. Clin Cancer Res . 13: 5544s-5548s. (Pubitemid 47510385)
158. Zillhardt M, Park S-M, Romero IL, Sawada K, Montag AG, Krausz T, Yamada SD, Peter ME, and Lengyel E (2011). Foretinib (GSK1363089), an orally available multi-kinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. Clin Cancer Res . 17: 4042-4051. Epub 2011 May 6.